The three major makers of insulin -- Eli Lilly, Sanofi and Novo Nordisk -- say they’ll participate in a voluntary Medicare Part D demonstration that caps beneficiaries’ monthly insulin costs at $35, but America’s Health Insurance Plans is still reviewing the demo, and without insurer participation it can’t go forward. The demo, announced Wednesday (March 11), applies to enhanced Part D plans that offer more generous drug coverage than basic drug plans, and it’s designed to have a minimal impact...